Seeking Alpha

Furiex Pharmaceuticals (FURX -1%) slips today, in spite of its earlier announcement of a $5M...

Furiex Pharmaceuticals (FURX -1%) slips today, in spite of its earlier announcement of a $5M milestone payment from the Menarini Group for the launch of Priligy in France. The drug is currently marketed by FURX  in 16 countries in Europe, Asia and Latin America, and is approved in 56 countries worldwide.  Under the it's agreement with Menarini, FURX is eligible to receive up to $40M in sales-based milestones, plus tiered royalties ranging from the mid-teens to mid-twenties in percentage terms.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|